Actively Recruiting
Adaptive Platform Trial Evaluating Treatments for Respiratory Infections in Community Settings Using Baloxavir and Placebo Controls
Led by Unity Health Toronto · Updated on 2026-08-18
264
Participants Needed
1
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an adaptive platform trial called TreatResp to evaluate treatments for respiratory infections in community settings, focusing on non-hospitalized patients. The trial aims to determine the clinical and cost-effectiveness of various therapeutics for respiratory pathogens like influenza AB and others. The study uses a randomized, double-blind approach to compare usual care against specific treatments, adapting as new therapies become available. Participants will be randomized to receive either usual care, which includes symptom relief and supportive care, or a study therapeutic selected by the TreatResp Therapeutics Committee. One such therapeutic being evaluated is Baloxavir, given as a single dose of 40 mg or 80 mg depending on the participants weight. The trial includes placebo controls matching Baloxavir. Treatments are administered in outpatient settings, with enrollment required within days of symptom onset. During the study, participants will report their symptoms daily and complete quality of life questionnaires over 28 days. Researchers will monitor time to recovery, emergency department visits, hospitalizations, deaths, symptom severity, and cost-effectiveness of treatments. Participation involves regular assessments and diary entries to track progress, with the primary outcome being the first day participants feel fully recovered.
CONDITIONS
Brief Title
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
Research Team
U
Upstream Lab Upstream Lab
T
TreatResp Study team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here